Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage Pharma & Biotech 2015 Preview

EP Vantage Pharma & Biotech Preview 2015

Download EP Vantage Pharma & Biotech 2015 Preview

Innovation will continue to drive the pharma and biotech sectors in 2015 as forecasts point to another prosperous year according to EP Vantage’s latest report, Pharma & Biotech 2015 Preview.


Key highlights in EP Vantage's Pharma & Biotech 2015 Preview:

  • A dozen products due to be launched next year are forecast to achieve blockbuster sales by 2020
  • Drugs treating high cholesterol and heart failure will dominate the field with a combined 2020 sales forecast of $8 billion
  • Sovaldi and its combination product Harvoni will take the number one worldwide seller spot with forecasted sales of $15.3 billion in 2015
  • Patent expiries will have minimal impact on the top line as 2015 sales will grow close to four times that of patent losses
  • Financing climate appears friendly and deals will continue at a steady pace but M&A activity unlikely to match the frenzy of 2014

Download EP Vantage Pharma & Biotech 2015 Preview

Press Release

Related Reports: 

EvaluatePharma Orphan Drug Report 2014

EvaluateMedtech World Preview 2014, Outlook to 2020

EvaluatePharma World Preview 2014, Outlook to 2020